Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Bone Miner Res. Author manuscript; available in PMC 2014 April 7.
Published in final edited form as:
PMCID: PMC3977219

Serum Response Factor Regulates Bone Formation via IGF-1 and Runx2 Signals


Serum response factor (SRF) plays vital roles in numerous cellular processes; however, the physiological function of SRF in skeletal tissue remains unknown. In several organ systems, SRF regulates the expression of insulin-like growth factor-1 (IGF-1), which is crucial for normal development of mineralized skeleton and bone remodeling throughout life. Here, we show that conditional deletion of SRF in osteoblasts by osteocalcin-Cre generated viable mice with normal body size and body weight. Compared with normal siblings, osteoblast-specific SRF-deficient adult mice exhibited a marked decrease in bone mineral density and bone formation rate. Deletion of SRF in primary mouse calvarial osteoblasts reduced cell differentiation and mineralization in vitro. This was accompanied by a decrease in IGF-1 expression and secretion. Addition of IGF-1 in the culture media enhanced osteoblast differentiation in control cells and partially restored the mineralization defect of SRF-deficient cells, supporting an important role of SRF in regulating IGF-1 and IGF-1-mediated osteoblast differentiation. IGF-1-induced Akt activation was inhibited in SRF-deficient calvarial cells and enhanced in the SRF overexpressed cells. In addition, SRF deficiency decreased the transcriptional activity of Runx2, the key transcription factor for osteogenesis. Overexpression of SRF induced Runx2 transactivity in control cells and restored Runx2 transactivity in the SRF-deficient cells. Taken together, we conclude that SRF is important for IGF-1-induced osteoblast differentiation and mineralization via regulating IGF-1 expression and Runx2 transactivity.

Keywords: Serum Response Factor, Insulin-Like Growth Factor, Akt, Runx2, Osteoblasts


Bone remodeling occurs throughout life to maintain bone size, shape, and integrity. The remodeling process is tightly regulated to maintain a balance between bone deposition by osteoblasts and resorption by osteoclasts.(14) Osteoblasts are differentiated from multipotential mesenchymal cells.(5) This differentiation process is regulated by local and systemically derived signals via cytokines, growth factors, hormones, and bone-specific transcription factors.(4,68) Insulin-like growth factors (IGFs) are important growth factors for the acquisition of bone mass during adolescence and maintenance of bone remodeling during adult life.(1,4,8) These secreted factors and related signaling pathways either promote or suppress the expression and/or function of transcription factors essential for osteoblast differentiation, directly or indirectly.(914) Runx2, predominantly expressed in osteoblasts, is obligatory for commitment of mesenchymal progenitors to the osteoblast lineage and for development of functional osteoblasts. Deletion of Runx2 in mice results in complete absence of bone formation, failure of osteoblast maturation, and perinatal lethality.(15)

Serum response factor (SRF) is a distinct and widely expressed MADS (Mcm1 and Arg80 in yeast, Agamous and Deficiens in plants, and SRF in animals) domain-containing transcription factor,(1618) which binds to the 10-bp consensus CArG box regulatory element to regulate gene transcription. SRF has been shown to regulate the expression of genes involved in diverse biological processes, including cell proliferation, differentiation, migration, survival, and apoptosis.(17) Depending on cell-type– specific cofactors, SRF may induce(19) or repress(20) target genes. SRF has relatively low intrinsic transcriptional activity, but its association with more than 60 cofactors confers strong transactivation potential in a cell- and context-specific manner.(21) SRF has been shown to regulate the expression of various molecules that play important roles in the development of several organ systems. For example, targeted deletion of SRF in cardiomyocytes and smooth muscle cells induces dilation of the heart and decreases smooth muscle cell recruitment to the dorsal aorta, resulting in embryo demise at embryonic day 10.5.(22) Furthermore, SRF is important for maintaining normal function of skeletal muscle,(23) liver,(24) pancreas,(25) neurons,(26) as well as lymphocytes and megakaryocytes.(27,28) However, the function of SRF in regulating skeletal development and bone remodeling is unknown.

To determine the role of SRF in regulating osteoblast differentiation and bone development in vivo, we generated osteoblast-specific SRF knockout mice by breeding SRF floxed mice(22) with the transgenic mice carrying the osteocalcin (OC) promoter-driven Cre recombinase.(2931) Osteoblast-specific deletion of SRF did not affect embryonic bone development but decreased bone mass of adult mice. Deletion of SRF in osteoblasts reduced osteoblast differentiation and mineralization in vitro, which was mediated by reduced expression and secretion of IGF-1 from osteoblasts and impaired IGF-1–induced Akt signals, as well as decreased Runx2 transactivity. These studies have demonstrated a novel function of SRF and SRF-regulated signals in osteoblast differentiation and bone formation.

Materials and Methods

Generation of osteoblast-specific SRF-deficient mice

The floxed SRF mice (SRFf/f) were generated as previously reported.(22) To generate osteoblast-specific SRF-deficient mice (SRFΔ/Δ), SRFf/f mice were crossed with osteocalcin-Cre (OC-Cre) transgenic mice(29) obtained from Dr Thomas Clemens (The Johns Hopkins University, Baltimore, MD, USA). The mice were maintained at the University of Alabama at Birmingham using Institutional Animal Care and Use Committee–approved procedures. Genotyping was carried out as previously described.(22,29)

Dual-energy X-ray absorptiometry (DXA) and microCT (μCT) analyses

DXA and μCT analyses were performed by the Small Animal Bone Phenotyping Core of the Center for Metabolic Bone Disease at the University of Alabama at Birmingham. Bone mineral density (BMD), bone mineral content, and other body composition were assessed by DXA (GE-Lunar PIXImus, version 1.45; GE-Lunar, Madison, WI, USA) in vivo periodically as described previously.(32) For μCT analysis, intact femur from each mouse was scanned using a high-resolution μCT imaging system (μCT40; SCANCO Medical, Wayne, PA, USA). Various bone parameters,(33) including bone volume and trabecular thickness, number, and space, were evaluated.

Bone histomorphometry analysis

Bone histomorphometry analysis was performed by the Histomorphometry and Molecular Analyses Core of Center for Metabolic Bone Disease at the University of Alabama at Birmingham. In brief, femurs were removed from 14-week-old mice and fixed in 10% formalin, decalcified in EDTA, and embedded in plastic polymers. Longitudinal sections (5μm thick) were stained with Goldner's modified Trichrome staining. Histomorphometric parameters, including bone volume and trabecular thickness, number, and space, were determined with Bioquant image analysis software (R & M Biometrics, Nashville, TN, USA) as previously described.(32) All parameters comply with the recommendations of the Histomorphometry Nomenclature Committee of the American Society of Bone and Mineral Research.(34)

In vitro osteoblast proliferation and differentiation

Primary mouse calvarial cells were isolated from newborn SRFΔ/Δ mice or SRFf/f mice by collagenase P digestion and cultured in growth media containing Minimum Essential Medium (Mediatech, Manassas, VA, USA) with 10% fetal bovine serum (Invitrogen, Grand Island, NY, USA). SRF knockout cells (SRF KO) were generated in vitro by deleting SRF in the SRFf/f cells using lentivirus-mediated Cre recombinase (lenti-Cre). Lentivirus-mediated GFP (lenti-GFP) was used as a control (Control). Cell proliferation was assessed by BrdU incorporation in 96-well plates using BrdU kit (EMD Millipore, San Diego, CA, USA). Osteoblast differentiation was induced in osteogenic media containing growth media supplemented with 50 μg/mL ascorbic acid (Sigma, St. Louis, MO, USA) and 10 mM β-glycerol phosphate (MP Biomedicals, Santa Ana, CA, USA).(35) Alizarin Red staining was used to determine mineralization. Samples were also collected to determine RNA and protein expression. The effect of IGF-1 on osteoblast formation was analyzed by addition of IGF-1 (13 nM, GroPep, Thebarton, Australia) in the culture media.(36)

Measurement of IGF-1

IGF-1 levels in the mouse sera or conditioned media of cell cultures were determined using a commercial ELISA kit (PeproTech, Rocky Hill, NJ, USA). For assaying serum IGF-1, mice were bled through retro-orbital vein, and serum samples were collected between 9:00 a.m. and 10 a.m. on a fed state. For assaying IGF-1 in the condition media, cells were placed in a 24-well plate and culture supernatants were collected. IGF-1 was measured using the ELISA kit.

Western blotting analysis

Calvarial cell extracts were prepared and protein concentrations were measured as described previously.(37) Western blotting analyses were performed with the use of specific antibodies for SRF, Sp1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Akt, phospho-Akt, ERK, phospho-ERK (Cell Signaling, Danvers, MA, USA), and Runx2 (MBL, Woburn, MA, USA) and detected with a Western blotting chemiluminescence detection kit (EMD Millipore, Billerica, MA, USA). Mouse monoclonal anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was purchased from Fitzgerald (Acton, MA, USA).

Real-time PCR analysis

To determine gene expression, total RNA was extracted per manufacturer's instructions (Invitrogen) and treated with RNase-free DNase I. The reverse transcription reaction was performed on 1 μg of RNA using the First Strand cDNA Synthesis Kit (Fermentas, Glen Burnie, MD, USA). Real-time PCR was performed and analyzed using SsoFast EvaGreen Supermix (Bio-Rad, Hercules, CA, USA) in a Bio-Rad CFX96-Cycler as previously described.(38)

Electrophoretic mobility shift assay (EMSA)

EMSA was performed to determine the Runx2 DNA binding activity. Nuclear extracts were extracted and analyzed using 32P-labeled probe containing Runx2-binding oligonucleotide from the Bglap2 promoter (underline, Runx 2 consensus): 5′-CAGAAACCAACCACAGGACCCAAACCACAGCCTCCAC-3′ as we previously described.(32) For supershift assays, nuclear extracts were preincubated with anti-Runx2 antibody or control mouse IgG for 20 minutes before the addition of the labeled probe. For competition experiments, an excessive amount of unlabeled probe (100-fold) was added to binding reactions.

Transfection and luciferase assays

To analyze Runx2 transactivity, calvarial cells were plated on 24-well plates at a density of 3 × 104 cells/cm2 and transfected with 0.2 μg of the pGL3-6 × OSE2 luciferase plasmid plus 0.1 μg of pCMV-β-galactosidase (β-gal) expression plasmid (control for transfection efficiency) using FuGene HD tranfection reagent (Roche, Indianapolis, IN, USA). Cells were then incubated for 72 hours and harvested to determine luciferase and β-gal activity. The luciferase reporter activity was normalized by β-gal activity (Promega, San Luis Obispo, CA, USA). To determine the effects of SRF on Runx2 transactivity, a lentivirus-carrying SRF expression construct was used, and lenti-GFP was used as a control. Overexpression of SRF was determined by Western blotting analysis.

Statistical analysis

Statistical analysis was performed as previously described.(32) Data shown are means ± standard deviation (SD). Differences between two groups were identified by Student's t tests. For multiple groups, one-way analysis of variance and Student-Newman-Keuls tests were used to identify differences. Significance was defined as p < 0.05.


Osteoblast-specific deletion of SRF reduces bone mass in adult mice

Osteoblast-specific SRF-deficient mice were generated by breeding SRF floxed mice with Cre transgenic mice in which the expression of Cre recombinase is driven by the promoter of osteocalcin (OC). The specificity and efficiency of OC-Cre-mediated recombination in osteoblasts has been verified previously.(29) The OC-Cre:SRFf/f mice (SRFΔ/Δ) were viable and fertile, with no apparent growth defects at birth.

To determine the effect of SRF deletion in osteoblasts on postnatal bone development, overall BMD was determined by whole-body DXA analysis of mice at the ages of 4, 6, 9, and 12 weeks. No significant difference in BMD was identified between SRFf/f and SRFΔ/Δ littermates at weeks 4 and 6. However, SRFΔ/Δ mice exhibited significantly reduced BMD at the ages of 9 and 12 weeks in both sexes (Fig. 1A). MicroCT analysis of the femurs confirmed that bone density was markedly decreased in SRFΔ/Δ mice (Fig. 1B). Quantitative analyses further demonstrated significant decrease in trabecular bone mass, indicated by the ratio of bone volume (BV) to tissue volume (TV), whereas cortical bone was not affected significantly in SRFΔ/Δ mice (Table 1). Consistently, decreases in trabecular numbers and thickness and increases in trabecular space were evident in the SRFΔ/Δ mice (Table 1). In addition, histomorphometrical analysis of the femurs revealed a marked decrease in trabecular bone density in SRFΔ/Δ mice (Fig. 1C, a1–a4). The thickness of the growth plate did not show any apparent changes in the SRFΔ/Δ mice, suggesting the osteoblast-specific deletion did not affect chondrocyte differentiation (Fig. 1C, b1–b4).

Fig. 1
Decreased bone densitometry in SRFΔ/Δ adult mice. (A) Bone mineral density (BMD) was assessed at 4,6, 9, and 12 weeks old in male and female mice. (B) Representative three-dimensional images of metaphyseal bone generated from μCT ...
Table 1
MicroCT Analysis of Bone Parameters in SRFf/f and SRFΔ/Δ Mice

SRF deletion confers decreased osteoblast differentiation

The cellular phenotype for SRF deletion was examined by ex vivo differentiation of calvarial osteoblasts from newborn SRFΔ/Δ mice. As shown in Fig. 2A, OC-Cre-driven SRF deletion did not occur efficiently in the calvarial cells from SRFΔ/Δ mice until week 3, at which time the cells are at the postproliferation stage to the mineralization stage during in vitro osteogenesis process. At week 4, the SRFΔ/Δ cells had reduced mineral deposition compared with the SRFf/f cells (Fig. 2B). Therefore, SRF deletion by OC-Cre occurred at the late stage of osteogenesis, and the SRF deletion at this stage reduced osteoblast mineralization.

Fig. 2
Reduced osteoblast differentiation in SRF-deficient calvarial cells. (A) Western blotting analysis of SRF in calvarial cells from SRFf/f mice and SRFΔ/Δ mice cultured in osteogenic medium for up to 4 weeks. (B) a, Alizarin Red staining ...

To further determine the effect of SRF on osteoblast differentiation and function, primary calvarial cells were isolated from SRFf/f mice, and SRF was excised by lenti-Cre (SRF KO). Western blotting analysis confirmed effective deletion of SRF in the SRF KO cells compared with that in control cells infected with lenti-GFP (Fig. 2C). In vitro osteogenic differentiation and matrix mineralization were markedly reduced in the SRF KO cells, whereas the control cells (lenti-GFP) exhibited a normal differentiation profile (Fig. 2D). Of note, SRF KO conferred a greater inhibition on osteoblast differentiation and mineralization compared with the SRFΔ/Δ cells, which may be owing to the fact that ex vivo deletion of SRF in the SRFΔ/Δ cells only occurred after 3 weeks in osteogenic media. In fact, deletion of SRF by lenti-Cre in SRFf/f calvarial cells significantly decreased cell proliferation by 30% (n = 3, p < 0.05), whereas calvarial cells from SRFΔ/Δ mice exhibited a similar proliferation rate as those from control SRFf/f mice (n = 3, not significant), suggesting additional effects of SRF on proliferation at an earlier stage.

SRF deletion reduces IGF-1 expression in primary calvarial cells

Because osteoblast-specific SRF deficiency was found to affect only adult mice in both sexes, we characterized the role of the growth factor IGF-1, one of the critical determinants of longitudinal bone growth, skeletal maturation, and acquisition of bone mass during puberty and thereafter.(8,39,40) SRF has been found to directly regulate IGF-1 expression in liver cells.(24) No significant differences of circulating IGF-1 levels were observed in sera from SRFf/f and SRFΔ/Δ mice (Fig. 3A). By contrast, IGF-1 expression and secretion were markedly reduced in the SRF KO osteoblasts (Fig. 3B). Quantitative real-time PCR analysis demonstrated a dramatic decrease in IGF-1 mRNA expression in the SRF KO osteoblasts compared with that in the control cells (Fig. 3C, left). The expression of the receptor for IGF-1 (IGF-1R) was similar in both control and SRF KO cells (Fig. 3C, right).

Fig. 3
Decreased IGF-1 expression in SRF-deficient osteoblasts. (A) Serum IGF-1 levels in SRFf/f and SRFΔ/Δ mice at 12 weeks of age (n = 5); (B) IGF-1 levels in culture supernatant of SRF KO and control osteoblasts. (C) Quantification of mRNA ...

IGF-1 enhances osteogenesis in SRF-deficient cells

To determine whether decreased IGF-1 expression in the SRF KO cells contributed to the decreased mineralization, we tested whether recombinant IGF-1 could rescue the phenotype. As determined by Alizarin red staining (Fig. 4A, B), addition of IGF-1 (13nM) in the osteogenic media during in vitro osteogenesis markedly increased mineralization of the control cells. In addition, IGF-1 also restored mineralization of the SRF KO cells.

Fig. 4
IGF-1 activated signaling in SRF-deficient osteoblasts. (A) IGF-1 enhances mineralization of osteoblast cells. SRF KO or control cells were cultured in differentiation medium with or without IGF-1 (13 nM). Mineralization was assessed by Alizarin Red staining ...

SRF deletion impairs IGF-1-activated signaling in primary calvarial cells

To determine whether SRF KO may affect IGF-1–induced signaling pathways, we characterized the two major signaling pathways that are activated by IGF-1, the protein kinase B (Akt) and extracellular signal-regulated kinase (ERK) signaling pathways.(41) IGF-1–induced activation and phosphorylation of Akt and ERK were evident in the control cells (Fig. 4C). The SRF KO did not affect IGF-1–induced ERK phosphorylation, whereas IGF-1– induced Akt phosphorylation was reduced. In addition, over-expression of SRF enhanced IGF-1–induced Akt phosphorylation (Fig. 4D). Therefore, SRF deletion in osteoblasts reduced IGF-1 expression and secretion by osteoblasts and inhibited IGF-1– activated Akt, which may contribute to the decreased differentiation and mineralization of osteoblasts in vitro.

SRF deletion inhibits Runx2 expression and Runx2 transactivity during osteogenesis

Runx2 is a key regulator for osteogenesis. Its expression and activity are regulated by many growth factors and signaling pathways, including IGF-1 and Akt.(42,43) Accordingly, we determined the effect of SRF KO on the Runx2 expression and activity. The expression of Runx2 was induced in the control cells that were cultured in osteogenic media for 10 days (Fig. 5A). By contrast, the induction of the Runx2 expression was significantly reduced in the SRF KO cells. Addition of IGF-1 in the culture media was able to enhance Runx2 expression in both control cells and SRF KO cells cultured either in growth or osteogenic medium (Fig. 5A).

Fig. 5
Effects of IGF-1 and SRF on Runx2 expression and DNA binding activity. (A) Western blotting analysis of nuclear expression of SRF and Runx2. SRF KO and control cells were cultured in differentiation media for 10 days, and nuclear extracts were prepared ...

The effect of SRF deletion on Runx2 DNA binding activity was determined by EMSA using a probe containing Runx2 DNA binding consensus. The specificity and efficiency of the probe for Runx2 DNA binding activity was validated with nuclear extracts from control cells (Fig. 5Ba). Osteogenic media induced Runx2 DNA binding activity in the control cells (Fig. 5Bb). In contrast, the activity was inhibited in the SRF KO cells. IGF-1 treatment enhanced the activity in both control and SRF KO cells (Fig. 5B). To further determine whether the altered Runx2 expression level was responsible for the effects of IGF-1 and SRF on the Runx2 DNA binding activity, we determined the activity in the Runx2-overexpressing cells. Overexpression of Runx2 in control and SRF KO cells was confirmed by Western blot analysis (Fig. 5C). Short treatment of IGF-1 for 30 minutes did not affect Runx2 expression (Fig. 5C) or Runx2 DNA binding activity (Fig. 5D). The Runx2 DNA binding activity appears to be similar in both control and SRF KO cells, indicating that SRF may not directly affect Runx2 DNA binding ability (Fig. 5D).

In contrast, despite Runx2 overexpression (Fig. 6A), the SRF KO cells exhibited decreased Runx2 transactivity (Fig. 6B), suggesting a role for SRF in regulating Runx2 activity as a transcription factor. To further determine the effect of SRF on Runx2 transactivity, SRF was overexpressed in control and SRF KO calvarial cells. Lentivirus-mediated overexpression of SRF was confirmed by Western blotting analysis (Fig. 6C). Runx2 transactivity was significantly decreased in the SRF KO calvarial cells as determined by the luciferase reporter assay (Fig. 6D, first set). Overexpression of SRF alone enhanced Runx2 transactivity in the control cells (Fig. 6D, white boxes). More important, the SRF overexpression restored Runx2 transactivity in the SRF KO cells (Fig. 6D, black boxes), supporting a role for SRF in regulating Runx2 transactivity in calvarial cells.

Fig. 6
Effects of SRF on Runx2 transactivity. (A, B) SRF deletion on Runx2 transactivity. (A) Western blotting analysis of SRF and Runx2. Control and SRF KO cells were cotransfected with pcDNA-Runx2 or empty vector, pGL3-6 × OSE2 and pCMV-β-gal, ...


Control of osteoblast differentiation and matrix mineralization is an intricate process requiring the interplay of cell signaling, transcriptional, and posttranscriptional regulatory events. In this study, we demonstrated that SRF is an important modulator for osteoblast mineralization and bone homeostasis. We found that osteoblast-specific deletion of SRF did not affect embryonic bone formation and chondrocyte maturation but decreased postnatal bone development of adult mice. The impact of osteoblast-specific deletion of SRF on the bone structure was similar in both male and female mice (Fig. 1), indicating that sex hormones are not involved. Furthermore, reduced bone mass of the osteoblast-specific SRF deletion mice was evident after week 9, suggesting the potential roles of growth factors.

We found that the SRF deletion significantly reduced the expression of IGF-1 in osteoblasts (Fig. 3C). Such an observation is consistent with those in skeletal muscle cells and liver cells in which SRF deficiency downregulates IGF-1.(24,44) IGF-1 is an abundant growth factor in bone, and osteoblasts are the main source for skeletal IGF-1 production.(45) The IGF-1/IGF-1R system is important in bone metabolism through a combination of endocrine, autocrine, and paracrine modes of action.(29,46) Especially during puberty, IGF-1 is indispensable for peak increases of BMDs via both growth hormone–dependent and –independent mechanisms. Targeted IGF-1 overexpression in osteoblasts increased trabecular bone volume at puberty.(47) In contrast, the development of peak BMD in the puberty was completely blocked in the IGF-1–deficient mice.(39) Similarly, we observed reduced bone mass in the osteoblast-specific SRF-deficient mice at the age of 9 weeks and thereafter (Fig. 1A). The timing of the bone phenotype in the osteoblast-specific SRF-deficient mice is strikingly similar to that of the IGF-1–deficient mice,(39) indicating that IGF-1 may mediate the effect of SRF on bone development. In addition, osteoblast-specific SRF deficiency resulted in bone loss prominently in the trabecular bone, but not in the cortical bones (Table 1). This is consistent with previous demonstration that local IGF-1 derived from osteoblast cells appears to play a significant role in the maintenance of trabecular bone.(47,48) We also found that the SRF deletion significantly reduced the expression of IGF-1 in osteoblasts but not in serum, suggesting the defect in locally expressed IGF by osteoblasts contributes to the decreased bone mass in the SRF-deficient mice after puberty (Fig. 3A). This also explains why cortical bones were not affected in the osteoblast-specific SRF-deficient mice because circulating IGF-1, mainly derived from the liver, contributes primarily to cortical bone integrity.(8) Therefore, decreased local IGF-1 expression by the SRF-deficient osteoblasts regulates trabecular bone loss in the SRFΔ/Δ mice. The in vitro osteogenesis studies further support an important role of IGF-1 in promoting osteoblast differentiation. Exogenous addition of IGF-1 enhanced osteoblast differentiation in normal control cells and partially restored osteoblast mineralization in the SRF deletion cells (Fig. 4A, B). In addition, SRF deletion did not affect osteoblast mineralization induced by bone morphogenic protein 2 (data not shown), which plays an important role in osteoblast differentiation, mineralization, and bone formation during early skeletal development.(49) Therefore, osteoblast-derived IGF-1 plays a critical and selective role in mediating the osteogenic function of SRF.

Ex vivo culture of calvarial cells from SRFΔ/Δ mice confirmed that SRF was decreased only when cells were cultured in osteogenic medium for 3 weeks or longer (Fig. 2A), at which time point cells were at a late stage of differentiation and mineralization.(50) In contrast, in vitro deletion of SRF in calvarial cells at an early stage resulted in more severe defects in osteoblast differentiation and mineralization (Fig. 2B, D), which may be attributed to decreased proliferation of the SRF KO cells. The additional role of SRF in regulating osteogenesis at the early proliferative stage is consistent with the function of SRF in regulating cell growth through the regulation of many growth factors and cell cycle genes.(21)

In addition to regulating IGF-1 expression by osteoblasts, SRF was also found to affect IGF-1–activated signals in osteoblasts. Upon IGF-1 binding, IGF-1R dimerizes and undergoes autophosphorylation, leading to the activation of insulin receptor substrates,(51) which activates two distinct pathways, including the phosphatidylinositol 3 kinase (PI3K)/Akt and ERK signaling pathways.(41) The activation of Akt and ERK signaling pathways is crucial for osteogenic differentiation from uncommitted mesenchymal precursor cells and for maturation of committed osteoblasts.(12,52) SRF deficiency selectively inhibited IGF-1– activated PI3K/Akt but not ERK signaling in calvarial cells (Fig. 4C), which was not owing to the effect of SRF on the expression of IGF-1 receptor. On the other hand, overexpression of SRF was found to enhance the IGF-1–induced activation of Akt, further supporting a direct role of SRF on IGF-1–induced activation of Akt signals.

Activation of Akt signaling pathways promotes osteoblast differentiation by inducing the expression and activity of several bone-specific genes, including the key osteogenic transcription factor, Runx2.(12,42,43) Runx2 is necessary and sufficient for commitment of mesenchymal progenitors to osteoblast lineage and for the development of functional osteoblasts.(53) In humans, Runx2 haploinsufficiency results in cleidocranial dysplasia, a disease characterized by defective bone formation and supernumerary teeth.(54) Multiple signaling pathways that affect osteoblast function converge on Runx2 signals.(55) Akt signaling has been reported to enhance DNA binding activity of Runx2, and Runx2 upregulates PI3K subunits, suggesting that Runx2 and Akt may be mutually regulated in osteoblasts.(42) We found that IGF-1 activated Akt signaling (Fig. 4) and enhanced Runx2 DNA binding activity (Fig. 5B), which was decreased by the SRF deficiency. In addition, induced Runx2 expression and activity during osteogenesis was inhibited in the SRF-deficient cells, which was associated with inhibition of Runx2 downstream target genes, such as Col1a1, osteocalcin, and Osterix (data not shown). Induction of Runx2 expression contributes to IGF-1– enhanced Runx2 DNA binding activity (Fig. 5A, B), as short-term IGF-1 treatment in Runx2-overexpressed cells did not affect Runx2 DNA binding activity (Fig. 5D). Deletion of SRF decreased Runx2 transactivity (Fig. 6A, B), without interfering with Runx2 DNA binding ability (Fig. 5C, D), whereas overexpression of SRF increased Runx2 transactivity in wild-type cells and restored Runx2 transactivity in the SRF KO (Fig. 6D). Previous studies have demonstrated that SRF interacts with Runx2 directly in murine C3H10T1/2 multipotential mesenchymal cell line.(56) Therefore, it is likely that SRF may serve as a cotranscription factor or affect Runx2 binding to other cofactors to regulate Runx2 transactivity in osteoblasts.

In summary, we have demonstrated that osteoblast-derived SRF regulates osteoblast mineralization and postnatal bone development of adult mice. Inhibition of IGF-1 expression, decreased IGF-1–activated Akt signaling and Runx2 activity, and reduced Runx2 transactivity by SRF deficiency in osteoblasts contributes differentially to the decreased osteoblast differentiation and function (Fig. 7). Our studies provide novel molecular insights into the function of SRF in regulating bone formation during postnatal skeletal development.

Fig. 7
A schematic model of SRF in regulating osteoblast formation. SRF positively regulates expression of IGF-1, IGF-1–activated Akt signals, and Runx2 DNA binding activity, as well as directly modulates Runx2 transactivity, which together enhances ...


The authors thank Jay M McDonald, MD (University of Alabama at Birmingham), for helpful discussion and critical review. We thank the Histomorphometry and Molecular Analyses Core Laboratory and the Small Animal Phenotyping Core of the Center for Metabolic Bone Disease at the University of Alabama at Birmingham, supported by National Institutes of Health Grant P30-AR46031 (Ponnazhagan S, PI). This work was supported in part by grants from the National Institutes of Health AR055339 (YC), HL092215 (YC), and HL-62572 (JMM), and by VA Merit Review Award BX000369 (YC).


Disclosures: All authors state that they have no conflicts of interest.

Authors' roles: Study design: JC, KY, JMM, HW, and YC. Study conduct and collection: JC, KY, and XM. Data analysis: JC, KY, HW, and YC. Drafting manuscript: JC and KY. Revising manuscript content: JMM, HW, and YC. All authors approved the final version of the manuscript. JC, KY, HW, and YC take responsibility for the integrity of the data analysis.


1. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest. 2005;115:3318–25. [PMC free article] [PubMed]
2. Hadjidakis DJ, Androulakis II. Bone remodeling. Ann NY Acad Sci. 2006;1092:385–96. [PubMed]
3. Khosla S, Westendorf JJ, Oursler MJ. Building bone to reverse osteoporosis and repair fractures. J Clin Invest. 2008;118:421–8. [PMC free article] [PubMed]
4. Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007;13:791–801. [PubMed]
5. Yin T, Li L. The stem cell niches in bone. J Clin Invest. 2006;116:1195–201. [PMC free article] [PubMed]
6. Baron R, Rawadi G, Roman-Roman S. Wnt signaling: a key regulator of bone mass. Curr Top Dev Biol. 2006;76:103–27. [PubMed]
7. Hu H, Hilton MJ, Tu X, Yu K, Ornitz DM, Long F. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development. 2005;132:49–60. [PubMed]
8. Giustina A, Mazziotti G, Canalis E. Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev. 2008;29:535–59. [PubMed]
9. Celil AB, Campbell PG. BMP-2 and insulin-like growth factor-I mediate Osterix (Osx) expression in human mesenchymal stem cells via the MAPK and protein kinase D signaling pathways. J Biol Chem. 2005;280:31353–9. [PubMed]
10. Celil AB, Hollinger JO, Campbell PG. Osx transcriptional regulation is mediated by additional pathways to BMP2/Smad signaling. J Cell Biochem. 2005;95:518–28. [PubMed]
11. Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ, Stein JL, Stein GS. Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr. 2004;14:1–41. [PubMed]
12. Mukherjee A, Rotwein P. Akt promotes BMP2-mediated osteoblast differentiation and bone development. J Cell Sci. 2009;122:716–26. [PubMed]
13. Mukherjee A, Wilson EM, Rotwein P. Selective signaling by Akt2 promotes bone morphogenetic protein 2-mediated osteoblast differentiation. Mol Cell Biol. 2010;30:1018–27. [PMC free article] [PubMed]
14. Qiao M, Shapiro P, Kumar R, Passaniti A. Insulin-like growth factor-1 regulates endogenous RUNX2 activity in endothelial cells through a phosphatidylinositol 3-kinase/ERK-dependent and Akt-independent signaling pathway. J Biol Chem. 2004;279:42709–18. [PubMed]
15. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89:755–64. [PubMed]
16. Messenguy F, Dubois E. Role of MADS box proteins and their cofactors in combinatorial control of gene expression and cell development. Gene. 2003;316:1–21. [PubMed]
17. Miano JM. Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol. 2003;35:577–93. [PubMed]
18. Shore P, Sharrocks AD. The MADS-box family of transcription factors. Eur J Biochem. 1995;229:1–13. [PubMed]
19. Posern G, Treisman R. Actin' together: serum response factor, its cofactors and the link to signal transduction. Trends Cell Biol. 2006;16:588–96. [PubMed]
20. Ernst WH, Janknecht R, Cahill MA, Nordheim A. Transcriptional repression mediated by the serum response factor. FEBS Lett. 1995;357:45–9. [PubMed]
21. Miano JM. Role of serum response factor in the pathogenesis of disease. Lab Invest. 2010;90:1274–84. [PubMed]
22. Miano JM, Ramanan N, Georger MA, de Mesy Bentley KL, Emerson RL, Balza RO, Jr, Xiao Q, Weiler H, Ginty DD, Misra RP. Restricted inactivation of serum response factor to the cardiovascular system. Proc Natl Acad Sci USA. 2004;101:17132–7. [PubMed]
23. Li S, Czubryt MP, McAnally J, Bassel-Duby R, Richardson JA, Wiebel FF, Nordheim A, Olson EN. Requirement for serum response factor for skeletal muscle growth and maturation revealed by tissue-specific gene deletion in mice. Proc Natl Acad Sci USA. 2005;102:1082–7. [PubMed]
24. Sun K, Battle MA, Misra RP, Duncan SA. Hepatocyte expression of serum response factor is essential for liver function, hepatocyte proliferation and survival, and postnatal body growth in mice. Hepatology. 2009;49:1645–54. [PMC free article] [PubMed]
25. Miralles F, Hebrard S, Lamotte L, Durel B, Gilgenkrantz H, Li Z, Daegelen D, Tuil D, Joshi RL. Conditional inactivation of the murine serum response factor in the pancreas leads to severe pancreatitis. Lab Invest. 2006;86:1020–36. [PubMed]
26. Etkin A, Alarcon JM, Weisberg SP, Touzani K, Huang YY, Nordheim A, Kandel ER. A role in learning for SRF: deletion in the adult forebrain disrupts LTD and the formation of an immediate memory of a novel context. Neuron. 2006;50:127–43. [PubMed]
27. Fleige A, Alberti S, Grobe L, Frischmann U, Geffers R, Muller W, Nordheim A, Schippers A. Serum response factor contributes selectively to lymphocyte development. J Biol Chem. 2007;282:24320–8. [PubMed]
28. Ragu C, Boukour S, Elain G, Wagner-Ballon O, Raslova H, Debili N, Olson EN, Daegelen D, Vainchenker W, Bernard OA, Penard-Lacronique V. The serum response factor (SRF)/megakaryocytic acute leukemia (MAL) network participates in megakaryocyte development. Leukemia. 2010;24:1227–30. [PubMed]
29. Zhang M, Xuan S, Bouxsein ML, von SD, Akeno N, Faugere MC, Malluche H, Zhao G, Rosen CJ, Efstratiadis A, Clemens TL. Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem. 2002;277:44005–12. [PubMed]
30. Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest. 2008;118:722–34. [PMC free article] [PubMed]
31. Chiang C, Chiu M, Moore AJ, Anderson PH, Ghasem-Zadeh A, McManus JF, Ma C, Seeman E, Clemens TL, Morris HA, Zajac JD, Davey RA. Mineralization and bone resorption are regulated by the androgen receptor in male mice. J Bone Miner Res. 2009;24:621–31. [PubMed]
32. Chen Y, Wang X, Di L, Fu G, Bai L, Liu J, Feng X, McDonald JM, Michalek S, He Y, Yu M, Fu YX, Wen R, Wu H, Wang D. Phospholipase Cgamma2 mediates RANKL-stimulated lymph node organogenesis and osteoclastogenesis. J Biol Chem. 2008;283:29593–601. [PubMed]
33. Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R. Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res. 2010;25:1468–86. [PubMed]
34. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987;2:595–610. [PubMed]
35. Brunner M, Millon-Fremillon A, Chevalier G, Nakchbandi IA, Mosher D, Block MR, Albiges-Rizo C, Bouvard D. Osteoblast mineralization requires beta1 integrin/ICAP-1-dependent fibronectin deposition. J Cell Biol. 2011;194:307–22. [PMC free article] [PubMed]
36. Fulzele K, DiGirolamo DJ, Liu Z, Xu J, Messina JL, Clemens TL. Disruption of the insulin-like growth factor type 1 receptor in osteoblasts enhances insulin signaling and action. J Biol Chem. 2007;282:25649–58. [PubMed]
37. Chen Y, Budd RC, Kelm RJ, Jr, Sobel BE, Schneider DJ. Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arterioscler Thromb Vasc Biol. 2006;26:1777–83. [PubMed]
38. Byon CH, Sun Y, Chen J, Yuan K, Mao X, Heath JM, Anderson PG, Tintut Y, Demer LL, Wang D, Chen Y. Runx2-upregulated receptor activator of nuclear factor kappaB ligand in calcifying smooth muscle cells promotes migration and osteoclastic differentiation of macrophages. Arterioscler Thromb Vasc Biol. 2011;31:1387–96. [PMC free article] [PubMed]
39. Mohan S, Richman C, Guo R, Amaar Y, Donahue LR, Wergedal J, Baylink DJ. Insulin-like growth factor regulates peak bone mineral density in mice by both growth hormone-dependent and -independent mechanisms. Endocrinology. 2003;144:929–36. [PMC free article] [PubMed]
40. van der Eerden BC, Karperien M, Wit JM. Systemic and local regulation of the growth plate. Endocr Rev. 2003;24:782–801. [PubMed]
41. Shelton JG, Steelman LS, White ER, McCubrey JA. Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle. 2004;3:372–9. [PubMed]
42. Fujita T, Azuma Y, Fukuyama R, Hattori Y, Yoshida C, Koida M, Ogita K, Komori T. Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J Cell Biol. 2004;166:85–95. [PMC free article] [PubMed]
43. Raucci A, Bellosta P, Grassi R, Basilico C, Mansukhani A. Osteoblast proliferation or differentiation is regulated by relative strengths of opposing signaling pathways. J Cell Physiol. 2008;215:442–51. [PubMed]
44. Charvet C, Houbron C, Parlakian A, Giordani J, Lahoute C, Bertrand A, Sotiropoulos A, Renou L, Schmitt A, Melki J, Li Z, Daegelen D, Tuil D. New role for serum response factor in postnatal skeletal muscle growth and regeneration via the interleukin 4 and insulin-like growth factor 1 pathways. Mol Cell Biol. 2006;26:6664–74. [PMC free article] [PubMed]
45. Rosen CJ, Donahue LR. Insulin-like growth factors and bone: the osteoporosis connection revisited. Proc Soc Exp Biol Med. 1998;219:1–7. [PubMed]
46. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest. 2002;110:771–81. [PMC free article] [PubMed]
47. Zhao G, Monier-Faugere MC, Langub MC, Geng Z, Nakayama T, Pike JW, Chernausek SD, Rosen CJ, Donahue LR, Malluche HH, Fagin JA, Clemens TL. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 2000;141:2674–82. [PubMed]
48. Machwate M, Zerath E, Holy X, Pastoureau P, Marie PJ. Insulin-like growth factor-I increases trabecular bone formation and osteoblastic cell proliferation in unloaded rats. Endocrinology. 1994;134:1031–8. [PubMed]
49. Li X, Cao X. BMP signaling and skeletogenesis. Ann NY Acad Sci. 2006;1068:26–40. [PubMed]
50. Javed A, Chen H, Ghori FY. Genetic and transcriptional control of bone formation. Oral Maxillofac Surg Clin North Am. 2010;22:283–93. [PMC free article] [PubMed]
51. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000;57:1050–93. [PubMed]
52. Taniguchi CM, Emanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006;7:85–96. [PubMed]
53. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997;89:747–54. [PubMed]
54. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JH, Owen MJ, Mertelsmann R, Zabel BU, Olsen BR. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell. 1997;89:773–9. [PubMed]
55. Franceschi RT, Xiao G, Jiang D, Gopalakrishnan R, Yang S, Reith E. Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation. Connect Tissue Res. 2003;44(Suppl 1):109–16. [PMC free article] [PubMed]
56. Tanaka T, Sato H, Doi H, Yoshida CA, Shimizu T, Matsui H, Yamazaki M, Akiyama H, Kawai-Kowase K, Iso T, Komori T, Arai M, Kurabayashi M. Runx2 represses myocardin-mediated differentiation and facilitates osteogenic conversion of vascular smooth muscle cells. Mol Cell Biol. 2008;28:1147–60. [PMC free article] [PubMed]